FindTrial
Sign In

Pemetrexed/Carboplatin

DRUG8 trials

Sponsors

Armando Santoro, MD, Pfizer, Henan Cancer Hospital, AstraZeneca, NextCure, Inc.

Conditions

Advanced or Metastatic Solid TumorsLung AdenocarcinomaMesotheliomaNSCLCNSCLC (Non-small Cell Lung Cancer)Non Small Cell Lung CancerNon-Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
WithdrawnNCT04430933
NextCure, Inc.Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
Start: 2021-12-06End: 2022-10-30Updated: 2021-08-18
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
RecruitingNCT04665206
Vivace Therapeutics, IncMesothelioma, NSCLC, Solid Tumor, Adult
Start: 2021-03-24End: 2030-03-02Target: 434Updated: 2026-04-02

Phase 2

Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients
TerminatedNCT00754364
Armando Santoro, MDNSCLC
Start: 2008-10-31End: 2015-12-31Updated: 2022-09-10
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
NCT02737774
Henan Cancer HospitalLung Adenocarcinoma
Start: 2016-04-13End: 2021-06-01Target: 60Updated: 2020-07-01
Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
Active, not recruitingNCT04769388
Beijing Cancer Prevention & Treatment SocietyNon Small Cell Lung Cancer
Start: 2021-12-28End: 2026-12-31Updated: 2026-01-12
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
RecruitingNCT05061550
AstraZenecaNon-small Cell Lung Cancer
Start: 2022-04-14End: 2030-05-28Target: 630Updated: 2026-03-11

Phase 3

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
CompletedNCT01639001
PfizerNSCLC (Non-small Cell Lung Cancer)
Start: 2012-09-29End: 2020-01-08Updated: 2020-12-08
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Active, not recruitingNCT04035486
AstraZenecaNon-Small Cell Lung Cancer
Start: 2019-07-02End: 2026-12-22Updated: 2025-10-10

Related Papers

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
2025-10-197 citations
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC.
2025-10-171 citations
Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with <scp>EGFR</scp> ‐Mutated Advanced <scp>NSCLC</scp>
Clinical Pharmacology & Therapeutics2025-07-104 citations
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
2025-05-316 citations
Ethnic disparities in clinical trials for FDA-approved drugs in lung cancer: A post-COVID era analysis (2020-2024).
Journal of Clinical Oncology2025-05-28
Neoadjuvant durvalumab (D) + chemotherapy (CT) + novel anticancer agents and adjuvant D ± novel agents in resectable non-small-cell lung cancer (NSCLC): Updated outcomes from NeoCOAST-2.
Journal of Clinical Oncology2025-05-28
Abstract 4728: The selective Yap/Tead inhibitor TY-1054 re-sensitizes acquired resistance to multiple tyrosine kinase-based targeted therapies
Cancer Research2025-04-21
EGFR mutation testing across the osimertinib clinical program.
2025-04-182 citations
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.
2024-10-219 citations
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer
Future Oncology2024-07-1830 citations
Abstract LB033: Identification of small molecule Pan-TEAD inhibitors disrupting YAP-TEAD protein-protein interaction and targeting gastric cancer cells
Cancer Research2024-04-051 citations
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
Cancers2024-03-0716 citations
4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes
ESMO Open2024-03-0122 citations
10P Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2
ESMO Open2024-03-014 citations
9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)
ESMO Open2024-03-012 citations
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
2023-12-1929 citations
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine2023-11-08530 citations
NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).
Journal of Clinical Oncology2023-06-0110 citations
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
Cancer Immunology Immunotherapy2023-04-0589 citations
Abstract 4491: TY-0584: A potent, orally available small molecule YAP/TEAD inhibitor, exhibits anti-tumor effects <i>in vitro</i> and <i>in vivo</i>
Cancer Research2023-04-043 citations

7 more papers not shown